FATE.NASDAQFate Therapeutics INC

SCHEDULE: Goldman Sachs Reports 2.0% Stake in Fate Therapeutics

Sentiment:

Beneficial Ownership Report

📋All filings for Fate Therapeutics INC
🔒Login to Follow

Goldman Sachs Group and Goldman Sachs & Co. LLC report beneficial ownership of 2.0% of Fate Therapeutics' common stock as of June 30, 2025.

Summary

  • The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G indicating their ownership stake in Fate Therapeutics, Inc.
  • As of June 30, 2025, the reporting persons beneficially own 2,274,020.09 shares of common stock, representing 2.0% of the class.
  • Goldman Sachs & Co. LLC, a subsidiary of The Goldman Sachs Group, Inc., holds shared voting power over 2,273,623.09 shares and shared dispositive power over 2,274,020.09 shares.

Sentiment

Score: 5

Explanation: The filing is a standard disclosure of ownership, with neutral sentiment.

Positives

  • Goldman Sachs' continued investment in Fate Therapeutics may signal confidence in the company's prospects.
  • The reported ownership is held in the ordinary course of business and not for influencing control of the issuer.

Future Outlook

NA

Industry Context

Schedule 13G filings are a routine part of the financial industry, providing transparency regarding significant ownership positions in publicly traded companies. This filing indicates Goldman Sachs' position in Fate Therapeutics, a company in the biotechnology sector.

Comparison to Industry Standards

  • Similar filings are made by institutional investors in comparable biotech companies, such as BlackRock's filings for CRISPR Therapeutics and Fidelity's filings for Editas Medicine.
  • A 2% stake is a fairly standard holding for institutional investors in companies of Fate Therapeutics' size and market capitalization.

Stakeholder Impact

  • Shareholders: The disclosure provides transparency regarding institutional ownership.
  • Employees: No direct impact on employees.
  • Customers: No direct impact on customers.
  • Suppliers: No direct impact on suppliers.
  • Creditors: No direct impact on creditors.

Key Dates

DateDescription
06/30/2025Date of event which requires filing of this statement (reporting date for ownership).
07/16/2025Date of Power of Attorney.
07/17/2025Date of filing and signatures.

Recommendation

hold

The filing is a routine disclosure of ownership and does not provide a basis for changing a hold recommendation. The 2% stake is not significant enough to warrant a change in recommendation.

Keywords

Fate Therapeutics, Goldman Sachs, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.